Trio of tactics to target COVID-19 hyperinflammation
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
Three companies announced COVID-19 programs Monday aimed at blocking the excessive inflammatory response seen in severe cases. Alexion unveiled a global program for its C5 inhibitor Ultomiris, while 4D pharma moved its live biotherapeutic therapy closer to the clinic, and Cyclacel partnered with the University of Edinburgh to test its pair of apoptosis regulators.
The programs join the more than 150 therapeutics in the clinic for COVID-19 (see “Daily Chart”).
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said it will start a Phase III trial of